BUZZ-Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation

Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 6.3% to A$14.100, their highest levels since February 7

Stock on track for its second consecutive session of gains, if trend holds

The drug manufacturer gets rare paediatric disease designation from the U.S. Food and Drug Administration (FDA)

Designation for NNZ-2591 in each of Pitt Hopkins syndrome and Angelman syndrome - Neuren

NNZ-2591 used for treatment of any traumatic brain injury

Stock has risen 11.6% so far this year, as of 0054 GMT